FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC

Joelle Fathi, DNP, Shares Key Nursing Implications of the New Formulation

Jan. 30, 2026 at 3:07pm

Got story updates? Submit your updates here. ›

The FDA has approved a subcutaneous formulation of the lung cancer drug amivantamab (Rybrevant Faspro) for patients with EGFR-mutated non-small cell lung cancer (NSCLC). This shift from intravenous (IV) infusions to subcutaneous injections promises greater convenience, autonomy, and potentially improved quality of life for patients. Oncology nurse expert Joelle Fathi, DNP, discusses the benefits for both patients and healthcare systems.

Why it matters

The approval of subcutaneous amivantamab represents a broader trend towards more patient-centric cancer treatment. Subcutaneous administration can dramatically reduce the time commitment and psychological burden for patients, while also increasing efficiency and resource allocation for healthcare providers. This evolution in delivery methods has the potential to transform the cancer care experience.

The details

The subcutaneous formulation of amivantamab allows patients to receive their medication through an injection under the skin, rather than the traditional intravenous (IV) infusion. This change can save patients significant time, with one study showing that patients receiving subcutaneous treatments reported lower levels of treatment-related fatigue and anxiety compared to those on IV regimens. For healthcare systems, the streamlined process translates to increased efficiency, allowing oncology centers to treat more patients with existing resources. The Cleveland Clinic, for example, reported a 15% increase in patient throughput in their thoracic oncology department after implementing a subcutaneous administration program.

  • The FDA approved the subcutaneous formulation of amivantamab (Rybrevant Faspro) on January 30, 2026.

The players

Joelle Fathi, DNP, RN, ARNP

Chief Healthcare Delivery Officer at GO2 for Lung Cancer, an expert on the nursing implications of the new subcutaneous amivantamab formulation.

Cleveland Clinic

A healthcare system that reported a 15% increase in patient throughput in their thoracic oncology department after implementing a subcutaneous administration program for select targeted therapies.

Got photos? Submit your photos here. ›

What they’re saying

“This medication offers an opportunity to regain some of their autonomy and their quality of life.”

— Joelle Fathi, DNP, RN, ARNP, Chief Healthcare Delivery Officer at GO2 for Lung Cancer (Cancer Nursing Today)

“You're not having to schedule a significant block of time for patients to come in...and monitor them while they're getting their IV administration.”

— Joelle Fathi, DNP, RN, ARNP, Chief Healthcare Delivery Officer at GO2 for Lung Cancer (Cancer Nursing Today)

What’s next

Oncology nurses will need to be proficient in subcutaneous injection techniques, patient education, and toxicity management to support this transition. Organizations like the Oncology Nursing Society (ONS) are providing resources and training to help nurses adapt to this evolving landscape.

The takeaway

The approval of subcutaneous amivantamab represents a significant step forward in patient-centered cancer care. By prioritizing convenience, autonomy, and quality of life, this shift in administration method has the potential to transform the cancer treatment experience for both patients and healthcare providers.